Given Imaging News

The results of the studies were presented at Digestive Disease WeekA , being held from May 19-22, 2012, in San Diego.

Given Imaging also announced new studies confirming PillCam A SB ' s benefits in several specialized patient populations, including octogenarians and those with neutropenic cancer, for whom the minimally-invasive procedure might be a safer alternative to other diagnostic methods.

An additional new study shows that BravoA pH monitoring for patients with gastroesophageal reflux disease can be extended to four days to increase findings.

Healthcare investor OrbiMed has closed a $222 million fund dedicated to life sciences venture capital deals based in Israel, the firm announced Monday.

Other equities research analysts have also recently issued reports about the stock.